REYON News
Total 39
The AAV gene therapy, under co-development of Reyon Pharmaceutical and Neuracle Genetics, has received approval for phase 1/2a clinical trials in Canada
2023.05.02
Reyon Pharmaceutical signed a joint development agreement with Therabest for NK cell therapy
2023.04.11
Reyon Pharmaceutical signed an MOU with Connext for comprehensive business cooperation in the CDMO business
2022.12.14
Reyon Pharmaceutical signed an MOU with Protium Science for comprehensive business cooperation for CDMO business
2022.12.06
Reyon Pharmaceutical signed an MOU with Therabest for business cooperation to supply pDNA samples
2022.11.24
Reyon Pharmaceutical signed an MOU with T&R Biofab for the joint development and commercialization of next-generation hemostatic agents
2022.10.25
Reyon Pharmaceutical and Neuracle Science discuss launching follow-up clinical trials for new antibody drugs against neurodegenerative diseases
2022.10.24
A GMP clinical-grade gene-therapy mass production system by Reyon Pharmaceutical and Samsung Seoul Hospital is selected as a national project
2022.09.23
Reyon Pharmaceutical participates in Bioplus-Interpex Korea 2022 for partnership expansion
2022.08.03
Reyon Pharmaceutical signed an MOU with Aston Science for joint R&D and commercializing a plasmid-DNA cancer treatment vaccine
2022.06.09
